IFITM-2 and IFITM-3 but Not IFITM-1 Restrict Rift Valley Fever Virus

I
n response to viral infections, nearly all vertebrate cells produce type I interferons (IFNs). This class of cytokines can induce expression of hundreds of IFN-stimulated genes (ISGs), thereby establishing an antiviral state in neighboring cells (1) . Consequently, an adaptive immune response is established and viral spread throughout the organism is diminished (reviewed in reference 2). Although there are many known ISGs, the antiviral mechanisms of only a few have been well characterized (reviewed in reference 3). Recent studies have identified the novel antiviral activity of a family of small ISGs known as interferon-induced transmembrane proteins (IFITMs). In humans, the IFITM family is composed of four functional genes, three of which (IFITM-1, -2, and -3) are ubiquitously expressed and induced by both type I and type II IFNs (4) (5) (6) , while expression of the fourth member (IFITM-5) is limited to osteoblasts (7) . IFITMs have been shown to restrict specific enveloped viruses, including influenza A virus (FLUAV) (8) , severe acute respiratory syndrome coronavirus (SARS-CoV), Ebola virus (EBOV), and Marburg virus (MARV) (9) , flaviviruses (including dengue virus types 1 and 2 [DENV-1/2] and West Nile virus [WNV]) (9, 10), HIV-1 (11) , and vesicular stomatitis Indiana virus (VSIV) (12) . In contrast, these proteins had no effect on murine leukemia virus (MLV) and arenaviruses, such as Lassa virus (LASV) and Machupo virus (MACV) (8, 9) . Furthermore, in vivo studies using IFITM-3-knockout mice, as well as humans possessing specific IFITM-3 gene mutations, have demonstrated that these individuals are more susceptible to disease caused by influenza A virus (13, 14) .
The molecular mechanisms by which IFITMs inhibit infection are still unclear, but accumulating evidence suggests that IFITM-3 alters the membranes of the vesicular compartments, such that virion-host membrane fusion is prevented and the endocytosed virions thereby remain trapped within the vesicles. For example, IFITM-3 did not inhibit the binding or entry of influenza A virus (8, 9, 15) or HIV-1 (11) but did prevent the release of ribonucleoprotein complex (RNP) into the cytoplasm. Additionally, IFITM-3 restriction of VSIV could be overcome by introducing viral genomic RNA directly into the cytoplasm (12) . IFITM-3 has been shown to partially reside in late endosomal and lysosomal compartments (9, 15, 16) , and its overexpression expands these acidified compartments (including Rab-5-, Rab-7-, and LAMP-1-coated vesicles) (15) . Previous work has shown that IFITMs possess differential antiviral activities against diverse viruses. IFITM-3 was most potent in resisting FLUAV, VSIV, WNV, and DENV infections, while IFITM-1 restriction of WNV and DENV infections was cell type dependent (9, 10, 12) . However, IFITM-1, -2, and -3 all restrict HIV-1, FLUAV, Ebola virus, and Marburg virus infections, but the efficiency of inhibition depended on the host cell type (9, 11, 15) . The mechanism behind the differential sensitivity of viruses to these proteins is not understood.
Rift Valley fever (RVF) virus (RVFV) is an emerging pathogen capable of causing serious epidemics among livestock and humans. RVFV was first described in 1931 (17) in East Africa and has since caused large eruptive disease throughout Africa and, more recently, on the Arabian Peninsula (reviewed in references 18 to 20). In domestic ruminants, RVF results in abortion and high fatality rates, especially among young animals. Although it is typ-ically a self-limiting febrile illness in humans, a small percentage of RVF cases develop severe viral hemorrhagic fever (VHF), neurological disorders, and/or blindness (21, 22) . Attenuated RVFV vaccine strains have been developed for prophylaxis (23) (24) (25) (26) , but to date there are no licensed drugs or vaccines approved in the United States. A better understanding of the life cycle of RVFV at the molecular level will undoubtedly help to develop effective vaccines and antivirals.
RVFV, a phlebovirus of the family Bunyaviridae, forms spherical enveloped virions that contain three single-stranded genomic RNAs (L, M, and S segments) of negative polarity that are encapsidated by nucleoprotein (NP) (27, 28) . Although the mechanism of RVF particle entry into host cells is not completely understood, it has been shown that the envelope glycoproteins (Gn and Gc) on the surface of the virion regulate cell entry via binding to an unknown cell surface receptor (29) (30) (31) . The endocytosed virions further undergo a low-pH-dependent membrane fusion (32) that leads to the release of the RNP into the cytoplasm. This mode of entry presents an attractive target for IFITM-mediated restriction. Furthermore, RVFV infection is highly sensitive to type I IFN, such that treating cells even with low doses of alpha IFN (IFN-␣) prior to infection inhibits viral replication (29, 33) . Therefore, RVFV infection serves as a useful model to explore the antiviral activity of individual ISGs, such as IFITMs.
In this study, we demonstrate that IFITM-2 and -3 but not IFITM-1 restrict RVFV infection mostly by preventing viral membrane fusion with the endosomes during virus entry. We further show that a large fraction of IFITM-1 resides in a vesicular compartment different from that occupied by IFITM-2 or -3. This has led to our speculation that IFITM-2 and -3 but not IFITM-1 are present at the sites of RVFV membrane fusion. Since other members of the Bunyaviridae family share a similar entry mechanism, we hypothesized that bunyaviruses may be restricted by IFITMs, similar to RVFV. We therefore analyzed IFITM regulation of bunyaviruses, including La Crosse virus (LACV), Hantaan virus (HTNV), Andes virus (ANDV), and Crimean-Congo hemorrhagic fever virus (CCHFV), which are all known to cause serious disease in animals and humans (reviewed in reference 34). IFITMs exhibited broad-spectrum antiviral activity against LACV, HTNV, and ANDV infections but not CCHFV infection. Interestingly, unlike RVFV infection, IFITM-1, -2, and -3 were all able to prevent LACV, HTNV, and ANDV infection with similar efficiencies. The implications of these findings are discussed.
MATERIALS AND METHODS
Cells, medium supplements, and viruses. HeLa, Vero E6, 293T, and A549 cells were maintained in Dulbecco's modified Eagle medium (Life Technologies) supplemented with 10% (vol/vol) fetal bovine serum (FBS; Life Technologies). Vero E6 cell lines stably expressing IFITM proteins were generated as described previously (9) and were maintained in complete growth medium supplemented with 4 g/ml puromycin (Life Technologies). Human IFN-␣2a (catalog no. 11100-1) was purchased from PBL Interferon Source. RVFV strains ZH548/MP-12 (MP-12) and ZH501 were obtained from The Salk Institute, Government Services Division, and from Michael Turell (United States Army Medical Research Institute of Infectious Diseases [USAMRIID]), respectively. The RVFV MP-12 strain, derived from virulent strain ZH548 of RVFV, is highly attenuated by several mutations (35, 36) , retains its sensitivity to IFN-␣ (37, 38) , and serves as an alternate model to the virulent RVFV strain that may be worked with under biosafety level 2 (BSL-2) laboratory conditions, unlike the virulent strains, which have to be handled in BSL-3 labs. RVFV ZH501 and RVFV MP-12 (passage 1) were propagated in Vero cells, and the virus from the supernatant was precipitated overnight at 4°C with 5% polyethylene glycol (molecular weight, 8,000; Sigma) and 2.3% NaCl (Sigma) and centrifuged at 17,000 ϫ g for 2 h. The virus pellet was resuspended in phosphate-buffered saline (PBS), aliquoted, and stored at Ϫ80°C. The Romero strain of Junín virus (JUNV) was propagated from a USAMRIID stock which was passaged five times in Vero cells. The passage 6 viral stock used in these experiments was propagated at a multiplicity of infection (MOI) of 0.01 in Vero cells and harvested on day 4 postinfection in a supernatant pool supplemented with 10% (vol/vol) FBS, aliquoted, and frozen at Ϫ80°C. ANDV, HTNV, and LACV were propagated in Vero E6 cells, and the virus-containing cell culture supernatant from the final passage was clarified by centrifugation at 12,000 ϫ g for 30 min, prior to aliquoting of the virus and storage at Ϫ80°C. CCHFV IbAr10200 was passaged twice in SW13 cells, twice in HepG2 cells, and twice in CER cells. The virus-containing cell culture supernatant from the final passage was clarified by centrifugation at 12,000 ϫ g for 30 min, prior to aliquoting of the virus and storage at Ϫ80°C. All virus stock titers were determined by plaque assay, as described below.
Plaque assays. RVFV, JUNV, and LACV yields were determined by a standard plaque assay, as previously described (39) , with minor changes. Briefly, serial 10-fold dilutions of each specimen were prepared in Eagle minimal essential medium (EMEM) with 10% (vol/vol) FBS added (Life Technologies). Two hundred microliters of each dilution was then adsorbed onto triplicate wells of Vero E6 cell monolayers for 1 h at 37°C in a 6-well plate. After 1 h, the monolayers were overlaid with 2 ml of a mixture of 1 part 1% (wt/vol) agarose and 1 part 2ϫ EMEM, 17 mM HEPES, 8% (vol/vol) fetal bovine serum, 100 U/ml of penicillin, and 100 g/ml of streptomycin sulfate (Life Technologies). After an appropriate time of incubation (3 to 4 days), when cytopathic effects began to appear, each cell monolayer was stained by adding 2 ml of a secondary overlay identical to the primary overlay but also containing 0.02% (wt/vol) neutral red (Sigma). After an additional 24 h of incubation, plaques were enumerated and viral titers were calculated. Infection assays. All cells used in the study, including HeLa, Vero E6, A549, or 293T cells, were infected with RVFV strain MP-12 or ZH501, LACV strain West Virginia-1997 (a kind gift from Michael Turell, USAM-RIID), JUNV strain Romero, HTNV strain 76-118, ANDV strain Chile-9717869, or CCHFV strain IbAr10200 at the indicated MOIs. Inocula were removed after 1 h, unless stated otherwise, washed with 1ϫ PBS, and replaced with the same amount of fresh medium. Infection was allowed to proceed for a specific duration of time, as described for each experiment. At the end of the incubation time, culture supernatants were collected to determine the virus yield by plaque assay or qRT-PCR analysis. Alternatively, cells infected with RVFV, JUNV, ANDV, HTNV, or CCHFV were fixed in 10% neutral buffered formalin (Val Tech Diagnostics) for 3 days and processed for immunofluorescence staining for image-based analysis.
qRT-PCR. RVFV RNA yields in the cells were determined by qRT-PCR using TaqMan-based probe sequences as previously described (40) .
In brief, total RNA from untreated cells (mock infected) or cells infected with RVFV were prepared using a MagMax 96 RNA extraction kit (Ambion). qRT-PCR assays were performed on an ABI Prism 7900HT sequence detection system with an RNA UltraSense one-step kit (Life Technologies) and TaqMan probes (Applied Biosystems) according to the manufacturers' instructions. Serial 10-fold dilutions of the assayed virus (10 2 to 10 7 copies) were used as standards. To determine relative levels of IFITM-1, IFITM-2, and IFITM-3 expression in IFN-␣-or siRNA-treated HeLa cells, total RNA was isolated at the indicated time points posttreatment using an RNeasy Plus minikit (Qiagen). Purified RNA was then measured with a Quant-IT RiboGreen RNA assay kit (Life Technologies). Fifty nanograms of each RNA was used in qRT-PCR assays under the same conditions described above with IFITM and PPIB TaqMan probes (Applied Biosystems). The target gene RNA or mRNA expression levels were normalized to the level of expression of the PPIB housekeeping gene. Relative expression levels were determined using the comparative threshold cycle (C T ) method (41) .
Staining of acidified compartments. Vero E6 cells stably expressing vector alone or IFITMs were incubated with LysoTracker red DND-99 or LysoTracker green DND-26 (Life Technologies) at 50 nM and 1 M concentrations, respectively, for 2 h. Cells were washed and replaced with medium containing Hoechst 33342 to stain nuclei, following which images were collected at a ϫ63 magnification on an Opera confocal reader, as described below.
Immunofluorescence studies. Formalin-fixed cells were untreated or, when indicated, permeabilized with 0.1% Triton X-100 (Sigma)-PBS for 15 min. Samples were then blocked in PBS containing 3% bovine serum albumin for 1 h, and proteins were stained with antibodies. The murine monoclonal antibody 4D4 detects the Gn portion of the glycoprotein of RVFV, and for rest of the report it is referred to as GP. The murine monoclonal antibody R3-ID8-1-1was used for visualizing the expression of the NP of RVFV. JUNV-infected cells were stained with the murine monoclonal antibody MA03-BE06 to detect expression of NP. ANDV and HTNV infection was measured by staining for their N protein using rabbit polyclonal antiserum specific to each virus's N protein (NR-9673 and NR-12152; BEI Resources). The murine monoclonal antibody 9D5-1-1A was used to detect CCHFV N protein in infected cells. IFITM-1, IFITM-2, and IFITM-3 were immunostained with antibodies from Proteintech with catalog no. 11727-3-AP, 12769-1-AP, and 11714-1AP, respectively. IF-ITM-2 and IFITM-3 antibodies cross-react and bind both IFITM-2 and -3 proteins but with reduced efficiencies. Mouse anti-Myc antibody (Sigma) was used to detect Myc-tagged IFITMs. Alexa 488-conjugated goat antimouse secondary antibody, Alexa 568-conjugated goat anti-rabbit antibody, or Alexa 647-conjugated goat anti-rabbit antibody (1:1,000; Life Technologies) was used to visualize primary antibodies. Cell nuclei and cytoplasm were labeled with Hoechst 33342 (Life Technologies) and HCS CellMask Red or Deep Red (Life Technologies) at a 1:10,000 dilution. Confocal images were collected with a Leica TCS-SP5 confocal/multiphoton microscope. High-content quantitative imaging data were acquired and analyzed on an Opera confocal reader (model 3842 [Quadruple Excitation High Sensitivity {QEHS]} or model 5025; PerkinElmer) at two exposures using a ϫ10 air objective or ϫ40 water objective. Analyses of the images were accomplished within the Opera or Columbus environment using standard Acapella scripts.
RESULTS
RVFV infection is restricted by overexpression of IFITM-2 and IFITM-3, but not by IFITM-1. Cell lines stably overexpressing
Myc-tagged IFITM-1, -2, or -3 or vector alone were generated in Vero E6 cells as described previously (9) . The expression of Myctagged IFITM proteins in these cell lines was analyzed by Western blotting (Fig. 1A) . In contrast to IFITM-1, IFITM-2 and IFITM-3 appeared as multiple bands and may represent the posttranslationally modified forms of the protein reported by other groups (16, 42) . These cell lines were infected with RVFV MP-12 ( Fig. 1B and C), RVFV ZH501 ( Fig. 1D and E ), or Junín virus (Fig. 1F ) at different MOIs and for various durations of time. The extent of infection was determined either by quantifying the percentage of cells expressing viral protein using image-based analysis or by plaque assay of the supernatants collected from virus-infected cells. Both RVFV ZH501 infection and RVFV MP-12 infection were restricted by IFITM-2 and IFITM-3, but not by IFITM-1 ( Fig. 1B to E) . IFITM-2-or -3-mediated restriction was relatively profound in cells infected at a lower MOI and at a specific window of time during infection. At higher MOIs, less restriction was observed, most likely because some infectious virions might have escaped IFITM restriction. Similar observations were made by plaque assay of the virus collected from the supernatants of RVFVinfected cells (Fig. 1E) . As a control, we also analyzed the infectivity of cells of the Vero E6 cell lines stably expressing IFITMs by infectious Junín virus (Romero strain), an arenavirus that we predicted would not be restricted by IFITMs (Fig. 1F) because previous studies showed that retroviruses pseudotyped with entry proteins of LASV or MACV were resistant to IFITM-mediated restriction (9, 15) . Similarly, our data showed that Junín virus was resistant to IFITM-mediated restriction (Fig. 1F ). More importantly, these data showed that IFITM-2 or -3 overexpression did not change the properties of cells such that these cells resisted virus replication nonspecifically. Furthermore, since both strains of RVFV-ZH501 and MP-12-had similar phenotypes, we chose to use MP-12 for the remaining studies.
Restriction of RVFV infection by IFITM-2 and -3 but not by IFITM-1 extends to all cell types tested. Previous studies have
shown that VSIV, WNV, and DENV-1/2, similar to RVFV, were restricted by IFITM-2 and -3 but not by IFITM-1 (10, 12) . However, this pattern of restriction was cell type dependent. IFITM-2 and -3 restricted VSIV, WNV, and DENV-1/2 infections in all the cell lines tested, while IFITM-1's repressive effect was limited to cell lines such as Vero E6, A549, or K562 and had no effect on cells of the 293T cell line (8, (10) (11) (12) . To test if the same applied to RVFV infection, we generated 293T, HeLa, and A549 human cell lines that stably overexpressed IFITM-1,-2, or -3 or vector alone and subjected them to RVFV infection (Fig. 2) . In all three cell lines, similar to the results for Vero E6 cells ( Fig. 1 ), IFITM-2 and -3 but not IFITM-1 restricted RVFV infection, suggesting that the phenotype observed was not cell type dependent. (1, 33, 34) . We determined the sensitivity of the RVFV MP-12 strain to type I IFN, as it was important to determine the lowest MOI of RVFV and the shortest duration of infection required to achieve an infection rate greater than 50% in HeLa cells, as IFITM-mediated viral restriction was the most profound in cells incubated with lower MOIs for a specific duration of time ( Fig. 1 ). HeLa cells were treated with increasing concentrations of IFN-␣ or left untreated for 24 h and subsequently infected with RVFV for another 24 h (Fig. 3A ) or 48 h (Fig. 3B ). Cells were then fixed, stained with virus-specific antibodies, and subjected to high-content quantitative image-based analysis to determine the percentage of infected cells. Our results indicated that incubation of RVFV at MOIs as low as 0.5 and 0.01 for periods of 24 h and 48 h, respectively, achieved an 80 to 100% infection rate in HeLa cells (Fig. 3A and B) . Treatment of HeLa cells with IFN-␣ revealed a concentration-dependent, potent inhibition of RVFV infection ( Fig. 3A and B) . Concentrations as low as 5 U/ml of IFN-␣ inhib-ited RVFV infection by 50% (Fig. 3A and B) , and the efficiency of inhibition was dependent on the MOI. At the same dose of IFN-␣, lower MOIs exhibited greater inhibition of infection. However, MOIs lower than 0.01, such as 0.005, were associated with larger variations. Consequently, experiments were limited to MOIs above 0.01.
IFN-␣ inhibits RVFV infection and induces IFITM gene expression in HeLa cells. RVFV infection is inhibited by type I IFN (IFN-␣/␤)
Furthermore, the level of induction of IFITM expression by IFN-␣ at its lowest dose (5 U/ml) that was sufficient to inhibit RVFV infection by greater than 50% was determined (Fig. 3C to  F) . HeLa cells were untreated or treated with 5 U/ml of IFN-␣ for various periods of time, followed by RNA extraction from cells to evaluate IFITM expression by qRT-PCR. Alternatively, cells were immunostained to detect IFITM expression at 24 h after IFN-␣ treatment. The images were acquired and subjected to high-content image-based analysis to determine the average fluorescent intensities of IFITM expression. As expected, the qRT-PCR data showed a time-dependent induction of IFITM-1, -2, and -3 expression under conditions of IFN-␣ induction (Fig. 3C) . IFITM-1 mRNA expression showed a higher degree of induction (ϳ4-fold) than IFITM-2 (ϳ2-fold) or IFITM-3 (ϳ3-fold) mRNA expression. However, the high degree of induction could have been due to the relatively very low levels of IFITM-1 mRNA expression under basal conditions that were reflected in higher C T values (data not shown). This observation was further supported by immunostaining data that showed very low to undetectable levels of IFITM-1 under basal conditions compared to the levels of IFITM-2 and -3 ( Fig. 3D to F) . Although IFN treatment induced IFITM-1 expression, IFITM-1 levels remained low compared to those of IFITM-2 or -3 (Fig. 3E ). Similar observations were made with IFITM antibodies from different vendors, suggesting that these differences were not due to differences in the antibody affinities (data not shown). For the rest of the study, HeLa cells were used in the context of IFN-␣ treatment to probe the mechanism of inhibition.
Depletion of IFITM-2 and IFITM-3, but not IFITM-1, enhances RVFV MP-12 infection. The optimized conditions depicted in Fig. 3A and B were applied to test how depletion of IFITM proteins under basal conditions influences RVFV infection of HeLa cells. To this end, HeLa cells were transfected with siRNA targeting IFITM-1, -2, or -3 singly or in combinations consisting of IFITM-2 and -3 or IFITM-1, -2, and -3. Forty-eight hours later, cells were infected with RVFV at an MOI of 0.05 for a period of 28 h, 36 h, or 42 h. Subsequently, cells were fixed and stained for high-content quantitative image-based analysis (Fig. 4A) . Compared with cells transfected with nontargeting siRNA, the percentage of RVFV-infected HeLa cells increased upon depletion of IFITM-2 or IFITM-3 (Fig. 4A ). This increase became more pronounced (by about 2-fold) when both IFITM-2 and -3 were depleted together and was similar to that when all IFITMs (IFITM-1, -2, and -3) were depleted. Moreover, as shown in Fig. 4A , the antiviral effects of IFITM-2 and -3 were profound at a specific window of time (36 h) and were not detectable with longer virus incubation (42 h). These findings further confirmed our earlier observations that with time and with increasing numbers of infectious virus particles, the virus is able to overcome IFITM restriction.
IFITM-2 and IFITM-3 mediate a large amount of the antiviral activity of IFN-␣ at lower levels. As IFN-␣ induced IFITM expression in HeLa cells (Fig. 3C to F), we tested whether a more profound effect on RVFV MP-12 infection could be observed upon depletion of IFITMs in IFN-␣-treated cells. To this end, HeLa cells were transfected with siRNA as described above (Fig.  4A) , and on the following day, cells were either left untreated or treated with increasing concentrations of IFN-␣ (Fig. 4B and C) . At 24 h after IFN-␣ treatment, cells were infected with RVFV for 42 h, fixed, and stained as described above. Consistent with our previous observations, even low doses of IFN-␣ (5 U/ml) potently inhibited RVFV infection (Fig. 4B) . Depletion of IFITM-2 or IFITM-3 proteins alone or together enhanced infection of cells compared to that for cells with IFITM-1 depletion or cells treated with nontargeting siRNA, and this increase in infection rates was more pronounced under IFN-␣-induced conditions than under IFN-␣-uninduced conditions ( Fig. 4B and C) . Interestingly, although hundreds of ISGs are induced by IFN, the antiviral effect of IFN-␣ at a lower dose of 5 U/ml could be mitigated by almost 50% by depleting IFITM-2 and -3 alone (compare the infection rates of the corresponding siRNA-transfected cells for IFN-␣-treated [5 U/ml] and untreated cells in Fig. 4B ). Although the knockdown of IFITM-2 and IFITM-3 increased infection by 6-fold at higher IFN-␣ doses (10 U/ml), it did not restore the infection rates to those observed in cells not treated with IFN-␣ (Fig. 4C) , indicating the overwhelming influence of other ISGs on RVFV infection at higher IFN doses. Therefore, for the rest of this study, IFN-␣ was used at 5 U/ml in HeLa cells to evaluate IFITM-mediated restriction of RVFV infection.
The target gene knockdown efficiency by siRNA treatment was determined by qRT-PCR analysis (Fig. 4D ) of cellular RNA that was extracted from cells transfected with siRNA for 24 h and then treated with IFN-␣ (5 U/ml) for another 24 h. Our data show that at the time of infection, the expression of the corresponding gene was inhibited by greater than 90% at the level of mRNA in cells transfected with siRNAs targeting IFITM-1, -2, or -3 or IFITM-2 and -3 simultaneously compared to the level of inhibition in cells transfected with nontargeting siRNA.
Kinetics of GP and NP expression during one round of replication of RVFV. To determine the stage of the virus life cycle that is restricted by IFITMs, we first characterized the kinetics and localization of viral GP and NP expression during the course of RVFV infection (Fig. 5) . HeLa cells were infected with RVFV for various lengths of time (4, 6, 8, 10 , or 12 h). Cells were then fixed, permeabilized, and stained with RVFV NP-or GP-specific antibodies to detect the expression of the corresponding viral proteins (Fig. 5A and B) . The virus egress from the cells was determined by cell surface staining for GP to detect GP expressed on the cell surface (S-GP) (Fig. 5B) , for which the permeabilization step during antibody staining was omitted. The percentage of cells that expressed NP, GP, or S-GP was determined by high-content quantitative image-based analysis (Fig. 5C and D) . As shown in Fig. 5A to C, viral NP expression reached a detectable level within 6 to 8 h postinfection, followed by GP expression at 8 to 10 h. Cell surface expression of GP (S-GP), which corresponds to virus egress, was observed at 10 to 12 h postinfection ( Fig. 5B and C) . This was further confirmed by plaque assay of the virus collected from cell culture supernatants (data not shown). Therefore, it appears that one round of RVFV replication takes 10 to 12 h. Interestingly, comparison of GP staining in permeabilized versus nonpermeabilized cells suggested that cytoplasmic GP took about 2 h to appear on the cell surface (Fig. 5B to D) . This observation was made at all the different MOIs (MOI, 0.5, 1, 2.5, 5, 7.5, or 10) that were tested (Fig. 5D) .
IFITM-2 and IFITM-3 proteins do not interfere with viral attachment or virion entry into cells. IFITMs restrict entry of FLUAV, WNV, SARS-CoV, DENV-1/2, VSIV, HIV-1, MARV, and EBOV (6, 12, 21, 23, 29, 43) . However, during HIV-1 infection, IFITM-1 did not inhibit viral entry but restricted viral replication (13) . In the absence of virus surrogates pseudotyped with RVFV entry proteins, the role(s) of IFITMs in RVFV cell attachment was analyzed by determining the amount of virus that associated with host cells during the course of infection by qRT-PCR analysis for viral RNA. Equal numbers of cells of each stable Vero E6 cell line expressing IFITM-1, -2, or -3 or control cells were plated at 100% confluence and incubated with RVFV for 5 min or 1 h on ice to promote virion attachment to the cell surface in the absence of endocytosis. Cells were washed extensively to remove unbound virus, and viral RNA associated with the cells was analyzed by qRT-PCR (Fig. 6A) . Our results demonstrated that there was no significant difference in the amount of virus RNA that was associated with control or IFITM-overexpressing cells.
By evaluating the time required for the virions to become resistant to ammonium chloride, we further determined how fast the virions, once attached to the cell surface, trafficked to endosomes to undergo membrane fusion. RVFV uncoating requires a low endosomal pH (32) . Ammonium chloride at a concentration of 20 mM raises the endosomal pH, thereby inhibiting virus membrane fusion without causing overall cytotoxicity. Thus, Vero E6 cells were incubated with RVFV at 4°C for 30 min to allow virus attachment but not internalization. Cells were then moved to a 37°C incubator, and 20 mM ammonium chloride was added over a period of time. After 12 h, cells were fixed and stained for viral GP expression. Within 30 min postattachment, about 50% of RVFV virions were endocytosed and viral uncoating was accomplished. We concluded that RVFV endocytosis is completed within 1 h postinfection, as more than 80% of RVFV virions became insensitive to ammonium chloride after 1 h of incubation (Fig. 6B) .
This time course was used to assess if IFITMs regulate virion endocytosis, as follows: Vero E6 cells stably expressing IFITMs or control cells were incubated with virus at 4°C for 1 h and rapidly moved to a 37°C incubator. At the indicated time points posttransfer to incubation at 37°C (Fig. 6C ), cells were treated with trypsin and washed extensively to remove cell surface-bound virions. Viral RNA within cells was then determined by qRT-PCR analysis of the M segment of the viral genomic RNA. There was a minimal increase in the amount of viral RNA within the cells as time progressed during the first 4 h of infection. However, at later time points, 6, 8, or 10 h postinfection, a gradual and significant increase in viral RNA copy number was observed. Furthermore, at these time points, IFITM-2-and -3-mediated restriction was apparent. These data are in agreement with those from our NP expression kinetics studies (Fig. 5) , in which RVFV NP expression was observed starting at 6 h postinfection, suggesting that at this time point viral transcription and replication are already under way. Taken together, our results indicate that IFITM proteins do not modulate virus attachment and internalization into cells. Therefore, the differences in viral RNA levels are most likely due to reduced viral replication or inhibition of the release of viral RNA from the endocytosed vesicles into the cytoplasm, where replication occurs.
IFITM-2 and IFITM-3 do not directly influence RVFV replication. On the basis of findings from previous studies of bunyaviruses, RVFV genomic RNA replication occurs in the cytoplasm of host cells after the endocytosed virion undergoes membrane fusion to release the ribonucleoprotein complex (RNP) into the cytoplasm (44) . It is possible to compare the kinetics of viral replication if the number of RNPs released into the cytoplasm is the same in control and IFITM-1-, -2-, or -3-expressing cells. This can be achieved by increasing the MOI of virus used to infect IFITM-2-or IFITM-3-overexpressing Vero E6 cells compared with that of virus used to infect control cells to compensate for any possible IFITM-2-or -3-mediated restriction that might occur following viral internalization but prior to replication. To measure the replication kinetics in these different cells, we reasoned that as viral RNA is packaged by NP, any changes in NP concentrations reflect the virus RNA replication status. Moreover, as mentioned above, our data showed that amplification of viral RNA and NP expression occurred at about the same time, at 6 to 8 h postinfection (compare Fig. 5C and 6C ). Taking this into account, RVFV replication kinetics were analyzed by quantifying the percentage of cells expressing NP during the course of infection. At 6 h postinfection, we found that control or IFITM-1 cells infected at an MOI of 0.5 yielded the same percentage of NP-expressing cells as IFITM-2-or IFITM-3-overexpressing cells infected at an MOI of 1 (Fig. 7) . Furthermore, as time progressed, the percentage of NP-positive cells remained similar among these populations of cells, suggesting no change in the kinetics of virus replication (Fig. 7) . Even when using the same MOI (0.5), the increase in infection rate over time was similar in all cell lines examined. From these data, we concluded that IFITM-2 or IFITM-3 proteins do not inhibit infection at the viral replication stage.
IFITM-2 and IFITM-3 restrict early stages of the RVFV life cycle. IFITM gene expression levels at the time of virus entry into the cell can be modulated by altering the IFN-␣ exposure time. Within 3 to 7 h of IFN-␣ addition to HeLa cells, IFITM concentrations began to increase progressively for the duration of the experiment (Fig. 3C) . Furthermore, most of the RVFV virions (Ͼ50%) entered cells during the first 30 min following virus attachment (Fig. 6B) . Therefore, to determine the time window at which elevated IFITM levels exert their antiviral activity over the course of RVFV infection, we treated HeLa cells with IFN-␣ at 24 h or 7 h prior to RVFV infection or at the time of virus addition to cells (Fig. 8) . IFN-␣-untreated cells were used as a control. Cells were also treated with siRNA targeting different IFITMs or control nontargeting siRNAs to examine how knockdown of the different IFITMs affected the RVFV infection rate under each of these IFN-␣ conditions. An MOI of 5 was used to achieve an infection rate of approximately 50% at 12 h of infection. The percentage of infected cells was monitored by quantifying the number of cells that stained positively for GP expression at 12 h postinfection, as this time span suffices for the virus to complete one replication cycle. Consistent with our previous findings with IFN-␣-untreated cells (Fig. 4A) , cells depleted of IFITM-2 and IFITM-3 had enhanced RVFV infection compared to control cells or cells depleted of IFITM-1. Treating cells with IFN-␣ for 24 h prior to infection resulted in a 2-fold inhibition of RVFV infection (Fig.  8A) , which was expected, as IFITM proteins reach high expression levels at this time point (Fig. 3C) . This inhibition was mitigated to a large extent by depleting IFITM-2 and IFITM-3. Interestingly, 7 h of IFN-␣ pretreatment resulted in approximately 20% inhibition of infection compared to the level of inhibition for cells not treated with IFN-␣ (Fig. 8B) and produced a small mitigation of this phenotype in IFITM-2-or -3-depleted cells (Fig. 8B) . Finally, treating cells with IFN-␣ at the same time as virus incubation with 4 cells/well in a 12-well plate) of the Vero E6 cell line stably expressing IFITM-1, -2, or -3 or empty vector were seeded overnight. Cells were incubated with virus at an MOI of 0.5 (solid lines) or 1 (dotted lines) for 1 h and washed to remove unbound virus, and the infection was allowed to proceed for the indicated times. Cells were stained with NP antibody, following which the images were acquired and the percentage of cells that stained positive for NP expression was determined. Data are presented as the percentage of infected cells, are representative of three independent experiments, and are the means Ϯ standard deviations. cells had no effect on RVFV infection, which was the same as the effect on cells not treated with IFN-␣. Together with our previous data, these results suggest that IFITM-2 and -3 target early events of the viral life cycle following viral internalization but prior to viral replication.
A majority of the IFITM-1 protein localizes to distinct compartments and does not localize with the IFITM-2 or -3 protein. Different members of the IFITM family restricted viruses with different efficiencies, and the efficiency of restriction was also dependent on the cell line model used for infection. Although IFITM-1 restricted EBOV, MARV, and HIV, it was dispensable for RVFV infection (9, 11) . It is possible that IFITM-1-coated vesicles are not the sites of RVFV virion membrane fusion. To test this, Vero E6 cells overexpressing Myc-tagged IFITM-1, IFITM-2, IFITM-3, or vector alone were stained with antibodies against Myc and IFITM-2 to detect the expression of exogenous Myctagged IFITM-1, -2, or -3 and endogenous IFITM-2, respectively. As shown in Fig. 9 , a large fraction of IFITM-1 did not colocalize with IFITM-2. Since the antibody against IFITM-2 cross-reacts with IFITM-3, we could not distinguish IFITM-2 from IFITM-3 staining. Therefore, it is possible that RVFV is not restricted by IFITM-1, as the compartments coated by IFITM-1 may not be the sites of virion uncoating.
Differences in the patterns of expansion of the acidified compartments by different members of the IFITM family. As shown in Fig. 9 , Vero E6 cell lines stably overexpressing IFITMs showed a large increase in the numbers of vesicular compartments that were coated by IFITM proteins (as seen with the differential interference contrast [DIC] image overlaid with the IFITMstained image). We further stained these compartments with two different LysoTracker dyes that stained the acidified compartments in the cell either red (Fig. 10A, top) or green (Fig. 10A,  bottom) . We observed not only a large increase in the acidified compartments, as shown previously with IFITM-3 (15), but also striking differences in the size (Fig. 10B ) and the number (Fig.  10C ) of these vesicular compartments among the IFITM family members. Interestingly, IFITM-1-overexpressing cells had large vesicles, with some reaching the size of the nucleus. The same pattern was also observed in HeLa, A549, and 293T cell lines overexpressing IFITMs (data not shown). The large vesicles exhibited a lower fluorescence intensity with LysoTracker dyes (below the background threshold) and were not recognized by the software as vesicles; therefore, they were excluded from the vesicle number and size analysis ( Fig. 10B and C) .
IFITMs exhibit broad-spectrum antiviral activity against several members of the Bunyaviridae family. We further tested if IFITMs can restrict infection by other members of the Bunyaviridae family (Fig. 11) . Bunyaviruses share similar virion morphologies with two envelope glycoproteins (Gn and Gc) that decorate their surfaces and appear to use similar pH-dependent cell entry pathways (30, (45) (46) (47) (48) . To examine if they also share sensitivity to IFITMs, we tested the infectivity of LACV (genus Orthobunyavirus), HTNV and ANDV (genus Hantavirus), and CCHFV (genus Nairovirus) in Vero E6 cell lines that stably expressed vector or the IFITM-1, -2, or -3 protein. With the exception of CCHFV, all viruses tested were restricted by IFITMs (Fig. 11) . In contrast to RVFV, IFITM-1 was able to suppress LACV, HTNV, and ANDV infection to the same extent as IFITM-2 or -3 (Fig. 11) . Further studies are warranted to more broadly examine the role of IFITMs in restriction of other viruses within the family Bunyaviridae.
DISCUSSION
The levels of IFITMs expression differ according to cell type and cytokine environment and can strongly impact the spread of viral infections (13) . Using cells of different cell lines, including Vero E6, HeLa, 293T, and A549, stably overexpressing IFITMs, we have shown that IFITM-2 and IFITM-3, but not IFITM-1, restrict both RVFV ZH501 and RVFV MP-12 ( Fig. 1 and 2) . Inhibition of infection can be profound, particularly when cells are exposed to relatively small amounts of virus (Fig. 1) . IFITM inhibition may therefore be important under natural infection conditions when RVFV hosts are exposed to just a few infectious virions. We have focused on the sensitivity of RVFV to IFN-␣ treatment to determine the effect of IFITM depletion on RVFV infectivity. The virus was sensitive to IFN-␣ treatment at concentrations as low as 5 U/ml (Fig. 3A and B) . Under these conditions, RVFV MP-12 infection was inhibited by greater than 70%. The level of inhibition was dependent on both the MOI of the virus and the duration of infection. Not only does IFN-␣ exposure suppress virus replication in cells (33) , but early studies also indicated that human IFN-␣ is effective in preventing viremia and fatal liver damage in RVFV-infected rhesus monkeys (35, 49) . Collectively, these data suggest that RVFV has evolved to suppress IFN-␣ production but that it cannot counter the antiviral activities of the downstream effectors of IFN-␣. Thus, RVFV serves as a very useful model to explore the antiviral mechanisms of ISGs. Strikingly, at low doses of IFN-␣ (5 U/ml), siRNA-mediated depletion of IFITM-2 and IFITM-3 alone mitigated the antiviral effect of IFN-␣ by 50% (Fig. 4A to C) . It is possible that IFITMs are induced and reach the threshold required to inhibit RVFV infection rapidly at smaller doses of IFN-␣ than other ISGs.
After we discovered the antiviral effects of IFITM-2 and -3 on RVFV infection, we wanted to examine the stage(s) in the virus replication cycle that is modulated by IFITMs. To this end, we characterized the single replication cycle of RVFV MP-12, including the expression of early and late viral proteins (NP and GP, respectively) (Fig. 5), virion egress (Fig. 5) , the kinetics of virion entry ( Fig. 6A and B) , and viral RNA transcription/replication ( Fig. 6C and 7) , with a combination of qRT-PCR and image-based analyses. As RVFV MP-12 is widely used for molecular characterization of RVFV infection, including for the development of highthroughput drug screening assays (50), the parameters determined should be useful to explore how infection modulators influence specific stages of the RVFV life cycle.
Our data indicate that RVFV attachment to the cell surface occurs rapidly and about 80% of the viral entry and uncoating happens during the first hour postinfection (Fig. 6) . A robust amplification of viral RNA was observed at 4 to 6 h postinfection (Fig.  4C) , followed by enhanced expression of viral NP and GP at 8 and 10 h, respectively (Fig. 5) . One round of viral replication took approximately 10 to 12 h. Application of these parameters to Vero cells stably overexpressing IFITMs showed that infection inhibition mediated by IFITMs does not happen at the level of virion attachment to cells (Fig. 6A) or entry into cells (Fig. 6C ) but occurs just before the initiation of viral RNA replication. This is because we did not observe any change in the kinetics of viral RNA replication in control or IFITM-overexpressing cells (Fig. 7) . Moreover, IFITM-2 and IFITM-3 modulate early events in the RVFV replication cycle, as upregulation of IFITMs after viral entry had no effect on virus infection (Fig. 8) . Therefore, similar to the findings for FLUAV, VSIV, and HIV-1, our data suggest that IFITM-2 and IFITM-3 might regulate RVFV membrane fusion by inhibiting viral membrane fusion and release of RNPs into the cytoplasm.
Several lines of evidence had previously suggested that IFITMs probably restrict viruses by inhibiting viral and endosomal membrane fusion, thereby restricting RNP release into the cytoplasm. First, studies with FLUAV and HIV-1 revealed that IFITM-3-overexpressing cells inhibit release of virion cores from the endosome into the cytoplasm (11, 15) . Second, IFITM restriction in WNV, DENV-1/2, and VSIV infection could be overcome by direct transfection of genomic viral RNA into cells (10, 12) . Third, IFITMs restrict cathepsin-dependent entry of SARS-CoV into the lysosome but do not restrict trypsin-induced fusion at or near the plasma membrane (13) . Collectively, these findings suggest that IFITMs probably modulate virus-host membrane fusion steps. The exact mechanism of this inhibition should be the focus of future studies.
Our data provide clues to the antiviral activity of IFITMs on the basis of the localization of IFITMs and their influence on vesicular compartments. Specifically, this study ( Fig. 9 and 10 ) and previous reports have shown that IFITMs are largely localized to the membranous regions of endosomes and lysosomes (9, 15, 16) . The membrane localization of IFITM-3 is critical for its antiviral activity. For instance, it is known that localization of IFITM-3 to endolysosomal fractions is positively regulated by S-palmitoylation and negatively by ubiquitinylation (16) . IFITM-3 mutants that cannot be palmitoylated or ubiquitinylated decrease or enhance the antiviral activity of IFITM-3, respectively, on the basis of their ability to localize to endolysosomal compartments. Furthermore, using Vero cells stably expressing IFITM-1, -2, or -3, we showed a large increase in both the size and number of vesicular compartments coated with IFITMs ( Fig. 9 and 10 ). These data are consistent with those from a recent study which showed that overexpression of IFITM-3 alone increased Rab-5, Rab-7, and LAMP-1 levels and the sizes of these compartments (15) . It appears that IFITMs modulate the biology of the vesicular compartments that they occupy and probably influence virus trafficking.
Another interesting finding from this study is the unique pattern of IFITM-mediated restriction, wherein IFITM-2 and -3 but not IFITM-1 inhibited RVFV infection in all cell types tested, including Vero E6 cells (Fig. 1) and HeLa, 293T, and A549 cells (Fig.  2) . Previous reports have shown a similar pattern of IFITM repression in VSIV, WNV, and DENV infection in some cell types, such as 293T cells, but not in other cell types, such as Vero E6 or K562 cells (8, (10) (11) (12) . In contrast, all three IFITMs restricted LACV, HTNV, and ANDV (Fig. 11A to C) , similar to the observations made in HIV-1 (11), FLUAV (8) , and MARV and EBOV (9) infections. A potential explanation for the differences in IFITM virus inhibition may lie in the viral fusion proteins that regulate virus-host membrane fusion and are categorized into three classes. The Gc protein of bunyavirus mediates viral membrane fusion and belongs to class II viral fusion proteins (51) . Even though the RVFV Gc fusion protein shares structural features with the LACV, HTNV, and ANDV Gc fusion proteins, RVFV is not restricted by IFITM-1, while LACV, HTNV, and ANDV are inhibited by IFITM-1 (Fig. 11) . This means that the type of fusion protein may not be a critical parameter. The other possibility is that IFITM-1 may not be present at the sites where RVFV virions are undergoing fusion. Our data support this possibility, as we observed that a majority of the IFITM-1 protein did not colocalize with IFITM-2 or -3 proteins (Fig. 9) . Our attempts to visualize virions trapped inside IFITM-coated compartments were not successful due to the large background of noninfectious virions. Our future studies will focus on addressing these issues, which will allow us to visualize and quantify virion entry and fusion. In ad- dition, marked differences in the ability to modulate vesicular compartments in the cells were noted among the IFITMs. IFITM-1-overexpressing cells formed very large vesicles ( Fig. 9 and 10) , with some of them being as large as the nucleus. Most of the large vesicles were not acid compartments, as they exhibited low fluorescence intensities (below the background threshold) with LysoTracker dyes whose fluorescence intensity increases at low pH (Fig. 10) . In addition, IFITMs were able to expand acidic compartments in the cells (Fig. 10) , with IFITM-2 and IFITM-3 causing the largest increases in the numbers and areas of acidic compartments, respectively. Combining all these observations, we postulate that different members of the IFITMs localize to distinct membrane regions, probably via binding to different cellular factors, and modify the membrane structure such that viral membrane fusion is inhibited. This will be the subject of our future studies.
In conclusion, the work presented here advances our understanding of RVFV infection and the antiviral activities of IFITM-2 and -3. Further studies focused on the properties of the IFITMcoated vesicles that lead to degradation of endocytosed viruses may provide additional information regarding the novel mechanism(s) regulating virus membrane fusion and, hopefully, inspiration for the development of new antiviral treatments.
